ROBIN MEDINA-REINHART: Open Payments
NPI 1013444165 · CLOVIS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,084 in 39 payments from 14 companies in 2025. Trend: 2023 $2,657 · 2024 $2,322 · 2025 $1,084
Food & beverage: $1,084
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $418 |
| AstraZeneca Pharmaceuticals LP | 5 | $160 |
| Novo Nordisk Inc | 4 | $83 |
| SANOFI-AVENTIS U.S. LLC | 3 | $71 |
| Ardelyx, Inc. | 4 | $71 |
| ViiV Healthcare Company | 2 | $50 |
| Dexcom, Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Lundbeck LLC | 1 | $33 |
| Lilly USA, LLC | 2 | $30 |
Products named: LINZESS, AIRSUPRA, TZIELD, IBSRELA, Ozempic, REXULTI, APRETUDE, Dexcom G6 Transmitter.
Industry payments across CA — which companies pay providers there.
